The secret sauce behind silver’s rally, Wells Fargo’s new pick for AI “super-cycle” leader, Huber Research’s grim view on the Netflix-WBD deal, and much more.
Dec 6, 2025
Apr 18, 2026
•
1 min read
Plus, a Permian Basin play that just got a 73% PT bump, a GPCR drug developer with 60% upside potential, and more...
Apr 11, 2026
2 min read
Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...
Apr 4, 2026
Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.